Project Grant R01AI183539
Award Date
6/12/25
Completion Date
5/31/30
Dollars Obligated
$391K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Scripps Research Institute to support research on developing a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase (NA) broadly neutralizing antibodies (bNAbs) and use directed evolution techniques to design NA immunogens that can engage diverse bNAb precursors. This "germline...
This $456,390.00 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is intended to fund research to understand how antigen duration and vaccine construct modulate the infant immune response to influenza vaccines. Specifically, the research seeks to elucidate the mechanisms by which a prolonged antigen delivery approach can significantly increase protective antibody...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...
This Project Grant award, valued at $1,500,314 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on engineering a hydrogel-based human immune organoid to generate antigen-specific germinal center (GC) B cells and enable forced affinity maturation ex vivo. The goal is to examine the in vivo engraftment of the engineered human B cells delivered via injectable gels. This innovative...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $668,569.00 to characterize and optimize a novel genetic vaccine platform called PARVAX. The key objectives are to: Investigate the mechanism behind the potency and durability of the PARVAX platform, hypothesized to be correlated with antigen expression kinetics. Use rational engineering approaches to enhance...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This Federal Project Grant award of $755,225.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel vaccine to prevent emerging pandemic coronaviruses. The key objectives are to: 1) Develop a papillomavirus-like particle (PV-VLP) based, T cell-inducing mucosal coronavirus vaccine targeting conserved coronavirus antigens (S2, M, and N) using gene rearrangement and...
This federal Project Grant award from the United States Department of Agriculture's National Institute of Food and Agriculture, under the Agriculture and Food Research Initiative (AFRI) CFDA 10.310 program, provides $648,881 to the University of Maryland, College Park to develop a mucosal vaccine for influenza that can prevent initial and recurrent infections and reduce transmission between animals and humans. The goal is to create a universal influenza vaccine delivered through a nasal spray...
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), will leverage machine learning to develop novel immunogen candidates for broadly protective influenza vaccines. The $1,195,056 award, effective from May 2025 to April 2030, aims to integrate artificial intelligence/machine learning (AI/ML) and traditional computational biology to create a new class of immunogens...